Back when it was fending off Pfizer’s hostile takeover attempt, AstraZeneca found support from some officials in the U.K. who blasted the deal on its potential…

Just a couple of days after Valeant board member Bill Ackman touted the company’s R&D program as an industry leader, it’s run into a snag.

Takeda is finally on the up-and-up after posting growth in its last fiscal year. And to help keep that growth coming, it’s exploring an asset sale to drum up…

The $250 million gender bias suit against Merck & Co. just picked up more steam.

Pharma marketers may have felt reprieved after a former Warner Chilcott sales chief was acquitted last month. But now, two former Johnson & Johnson execs…

Biogen CEO George Scangos is going out on an up note. The biotech, which today reported street-beating Q2 results, said he is stepping down as soon as a…

AstraZeneca’s ZS-9 setback last month did Relypsa a favor: It handed Veltassa sole control of the hyperkalemia market. That didn't hurt Relypsa’s chances…

Gilead may have won the patent manipulation suit thrown its way earlier this year by the AIDS Healthcare Foundation. But outrage over its pricing practices and…

With both U.S. presidential candidates promising action on drug prices, November’s election could trigger a sea change in the industry, Novartis CEO Joe…